Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease.
about
Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary diseaseExtrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary diseaseCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseLong acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease.Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.COPD: maximization of bronchodilation.Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature.Advances in the management of chronic obstructive pulmonary disease.Long-acting inhaled beta 2-agonists for stable COPD.Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary diseaseFormoterol: a review of its use in chronic obstructive pulmonary disease.Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.Formoterol in the management of chronic obstructive pulmonary disease.Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function.Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol.Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.Formoterol fumarate inhalation solution (Perforomist) for COPD.Current issues in the management of chronic obstructive pulmonary diseases.Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.Eformoterol n-of-1 trials in chronic obstructive pulmonary disease poorly reversible to salbutamol.
P2860
Q24245141-842E871D-48C4-4AB2-8890-A329184AA6ADQ26745663-211C4935-4654-43AC-B5A4-DA0B2C4EAB51Q27012625-9578DDFB-4DD6-4B6F-950C-AE3FEAC57AE7Q33691291-17820281-B156-4CDB-97FB-853CBE5FCB1AQ33783760-4D31493D-FE61-4DDD-B16D-EA5EACD8253EQ34436393-846B764C-5E75-48B0-842A-351467FEE1B9Q34834664-4CD96AF2-8D7E-4691-8520-D507A026A1A2Q35164693-3D8D48E6-0A0F-44E4-9465-21B89FFDF3E3Q35201031-68512E40-C7EE-42DF-9E1C-382CCBC2808AQ35573056-9349BCA3-BD98-4534-9FB3-BAD7544BD01DQ35627824-6406EBAD-BEB8-4BDE-ADC3-935721431A5AQ35841604-393E0929-02D7-4E38-9630-A63B90239802Q37070307-4CB2D100-10F3-4953-B561-FB5253B6C935Q37310689-CFE098EA-949E-4F72-8636-E6083FE545BCQ37622938-C8C7B2A8-0160-4E62-9DC4-062B164EBB73Q37911291-E2E6FD3E-2A81-4FA3-BEC4-37BEAFCDF6B1Q38477843-9D77AF56-A2A9-4889-80EC-32E390BFEAA2Q39317855-F7DC78D9-FDD8-45F2-86FC-4B0649D8F1ECQ41662462-C359F4A0-ADC4-4747-AA03-5F4CF1BEE013Q43732336-2E9E29AF-2062-452B-96DE-A4D52CE113CCQ46797788-367D8960-2B43-4AB7-BDCB-2D09FBBE6C47
P2860
Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Effect of salmeterol and formo ...... obstructive pulmonary disease.
@en
Effect of salmeterol and formo ...... obstructive pulmonary disease.
@nl
type
label
Effect of salmeterol and formo ...... obstructive pulmonary disease.
@en
Effect of salmeterol and formo ...... obstructive pulmonary disease.
@nl
prefLabel
Effect of salmeterol and formo ...... obstructive pulmonary disease.
@en
Effect of salmeterol and formo ...... obstructive pulmonary disease.
@nl
P2093
P356
P1476
Effect of salmeterol and formo ...... obstructive pulmonary disease.
@en
P2093
A Salzillo
G Santangelo
M G Matera
P304
P356
10.1006/PULP.1994.1012
P577
1994-04-01T00:00:00Z